UK exclusive DECLARE research presented at DPC2018 now available to view
Diabetes Professional Care 2018 (DPC2018) gave UK healthcare professionals an exclusive first look at the outcomes data from a DECLARE study on the impact of SGLT2 inhibitors on people with type 2 diabetes with high CV risk.
Professor John Wilding, Professor of Medicine & Honorary Consultant Physician, Obesity & Endocrinology Research, University of Liverpool, presented the findings at DPC2018 on World Diabetes Day.
The cutting-edge study – which recruited over 17,000 people with type 2 diabetes at high CV risk – found that dapagliflozin had a broadly positive effect on cardiovascular (CV) outcomes, especially heart failure (HF), in patients with type 2 diabetes.
Click the video below to view the presentation, for free.
Cardiovascular outcomes with SGLT2 inhibitors in type 2 diabetes – update from AHA conference
Professor John Wilding, Professor of Medicine & Honorary Consultant Physician, Obesity & Endocrinology Research, University of Liverpool
Join us on 29 & 30 October for the latest diabetes research findings and valuable real-world learning about the prevention, treatment and management of diabetes, and its related conditions.
*Please note, this content is intended specifically for registered healthcare professionals only.